Notably, we cannot exclude a pathogenic role of tau in humans with PD or other synucleinopathies or that tau reduction might be of benefit in specific forms of PD, for example, those caused by LRRK2 mutations [37]. This evidence concerns the gene MAPT and synucleinopathy.